KKR-backed hospital chain Radiant Lifecare submits its bid for Fortis Healthcare

Radiant Lifecare, the emerging Mumbai-based hospital chain that is backed by buyout firm KKR, has submitted its bid for Fortis Healthcare, the cash-strapped hospital network that is in the middle of a fiercely contested bidding war.

Radiant has made a offer for Rs 165 per share, which comes to Rs 6,500 crore for Fortis healthcare.

Seperately, the company said will offer Rs 3,600 for SRL. SRL will be spun off and Fortis shareholders will get its shares.

This takes the total deal value to Rs 10,000 crore. Radiant has offered to inject cash immediately in the company by buying the FMRI and Shalimar Bagh hospitals that are outside the RHT trusts.

Radiant Hospitals which raised $200 million from private equity firm KKR last year has been looking for hospital assets with minimum 500 beds to acquire and expand its operations. Currently in possession with two hospitals in Delhi and Mumbai, Radiant says it wants to expand in metro cities.

  • Related Posts

    Glenmark Pharma’s US arm launches Latanoprost’s bioequivalent solution

    Glenmark Pharmaceuticals said that US-based Glenmark Pharmaceuticals Inc. has launched Latanoprost Ophthalmic Solution. The aforementioned solution is bioequivalent and therapeutically equivalent to the reference listed drug Xalatan Ophthalmic Solution of…

    HC denies bail to pharma company owner for manufacturing spurious drugs

    Shimla:  The Himachal Pradesh high court on Monday declined bail to the owner of pharmaceutical company M/s Glenmars Healthcare in the Baddi area of Solan district, from where a huge…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Very Arty Surgery for Weight Loss by SSI Mantra, World’s First

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Pills & Profits: Can India’s pharma sector handle Trump’s planned 200% tariff dose?

    Novartis wins approval for first malaria drug for newborns and babies

    Novartis wins approval for first malaria drug for newborns and babies

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr

    Nectar to sell API, formulations & menthol biz to Ceph Lifesciences for Rs 1,290 cr